Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells $64,260.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the transaction, the chief executive officer now directly owns 749,087 shares in the company, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Friday, March 22nd, Daniel Faga sold 145,940 shares of AnaptysBio stock. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20.
• On Monday, January 8th, Daniel Faga sold 6,866 shares of AnaptysBio stock. The stock was sold at an average price of $21.81, for a total value of $149,747.46.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $22.52 on Friday. The stock has a 50-day simple moving average of $23.97 and a two-hundred day simple moving average of $20.23. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $27.50. The firm has a market capitalization of $602.64 million, a PE ratio of -3.70 and a beta of -0.28.

Institutional Trading of AnaptysBio

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in AnaptysBio by 2.1% during the first quarter. BlackRock Inc. now owns 1,895,494 shares of the biotechnology company’s stock valued at $41,246,000 after purchasing an additional 39,228 shares during the period. Vanguard Group Inc. grew its holdings in AnaptysBio by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,745,108 shares of the biotechnology company’s stock valued at $44,518,000 after purchasing an additional 14,638 shares during the period. State Street Corp lifted its position in shares of AnaptysBio by 10.0% in the third quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock valued at $32,442,000 after acquiring an additional 115,846 shares in the last quarter. First Light Asset Management LLC lifted its position in shares of AnaptysBio by 56.4% in the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after acquiring an additional 446,372 shares in the last quarter. Finally, Braidwell LP lifted its position in shares of AnaptysBio by 18.6% in the second quarter. Braidwell LP now owns 1,154,423 shares of the biotechnology company’s stock valued at $23,481,000 after acquiring an additional 181,350 shares in the last quarter.

Analysts Set New Price Targets

ANAB has been the topic of a number of recent research reports. Stifel Nicolaus assumed coverage on AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective on the stock. BTIG Research assumed coverage on AnaptysBio in a research report on Monday, February 26th. They set a “buy” rating and a $55.00 price target on the stock. Piper Sandler started coverage on AnaptysBio in a research report on Friday, February 16th. They set an “overweight” rating and a $80.00 price target on the stock. Finally, Wedbush upgraded AnaptysBio from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus target price of $45.00.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.